FIGURE 2.

Timeline illustrating the rapidly progressive development in FDA approvals of PD‐1 and PD‐L1 inhibitor‐based therapies in different cancers since pembrolizumab was approved as the first PD‐1/PD‐L1 inhibitor in 2014. Data was retrieved from https://www.cancerresearch.org. Abbreviations: M Monotherapy, NSCLC Non‐small cell lung cancer, HNC Head and neck cancer, HL Hodgkin lymphoma, C Combination therapy, MSI‐H Microsatellite instability high, dMMR Mismatch repair deficiency, PMBCL Primary mediastinal large B‐cell lymphoma, HCC Hepatocellular carcinoma, MCC Merkel cell carcinoma, SCC squamous cell carcinoma, SLCL Small‐cell lung cancer, TMB Tumour mutational burden, RCC Renal cell carcinoma, CRC Colorectal cancer. Created with BioRender.com